Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Ланреотид в лечении больных c диссеминированными высокодифференцированными нейроэндокринными опухолями: опыт применения при неудовлетворительной переносимости октреотида
Ланреотид в лечении больных c диссеминированными высокодифференцированными нейроэндокринными опухолями: опыт применения при неудовлетворительной переносимости октреотида
Емельянова Г.С., Кузьминов А.Е., Орел Н.Ф. Ланреотид в лечении больных c диссеминированными высокодифференцированными нейроэндокринными опухолями: опыт применения при неудовлетворительной переносимости октреотида. Современная Онкология. 2016; 18 (1): 80–83.
Oncology. 2016; 18 (1): 80–83.
________________________________________________
Oncology. 2016; 18 (1): 80–83.
Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Аннотация
Аналоги соматостатина играют ключевую роль в лечении диссеминированных высокодифференцированных нейроэндокринных опухолей (НЭО), как функционирующих, так и нефункционирующих. Воздействуя на рецепторы соматостатина, они ингибируют гормональную активность НЭО и оказывают прямой антипролиферативный эффект, увеличивая медиану времени до прогрессирования. Примерно у 10% больных имеются выраженные побочные эффекты при применении октреотида. Октреотид и ланреотид различаются по структуре и аналогами не являются. Так, при непереносимости одного препарата он может быть заменен на другой.
Ключевые слова: нейроэндокринные опухоли, октреотид, ланреотид.
Key words: neuroendocrine tumors, octreotide, lanreotide.
Ключевые слова: нейроэндокринные опухоли, октреотид, ланреотид.
________________________________________________
Key words: neuroendocrine tumors, octreotide, lanreotide.
Полный текст
Список литературы
1. Patel YC, Murthy KK, Escher EE et al. Mechanism of action of somatostatin: an overview of receptor function and studies of the molecular characterization and purification of somatostatin receptor proteins. Metabolism 1990; 39 (9 Suppl. 2): 63–9.
2. Lahlou H, Guillermet J, Hortala M et al. Molecular signaling of somatostatin receptors. Ann N Y Acad Sci 2004; 1014: 121–31.
3. Rorstad O. Prognostic indicators for carcinoid neuroendocrine tumors of the gastrointestinal tract. J Surg Oncol 2005; 89: 151–60.
4. Bajetta E, Carnagi С, Ferrari L et al. The role of somatostatin analogues in the treatment of gastroenteropancreatic endocrine tumors. Digest 1996; 57 (Suppl. 1): 72–7.
5. Battershill PE, Clissold SP. Octreotide: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in conditions associated with excessive peptide secretion. Drugs 1989; 38: 658–702.
6. Kvols LK, Moertel CG, O'Connell MJ et al. Treatment of the malignant carcinoid syndrome. Evaluation of a long-acting somatostatin analogue. N Engl J Med 1986; 315 (11): 663–6.
7. Lightman S. Somatuline autogel: An eхtended release lanreotide formularion. Hosp 2002; 315: 246–54.
8. Oberg K, Kvols LK, Caplin M et al. Consensus report on the se of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system. Ann Oncol 2004; 15 (6): 966–73.
9. Ricci S, Antonuzzo A, Galli L et al. Long-acting depot lanreotide in the treatment of patients with advanced neuroendocrine tumors. Am J Clin Oncol 2000; 23 (4): 412–5.
10. Kaltsas GA, Stefanidou Z, Papadogias D, Grossman AB. Treatmentof advanced neuroendocrine tumors with the radiolabelled somatostatin analogue octreotide. Hormones (Athens). 2002; 1 (3): 149–56.
11. Grozinssky-Glasberg S, Shimov I, Korbonits M, Grossvan AB. Somatostatin analogues in control of the control of neuroendocrine tumors: efficacy and mechanisms. Endocr Relat Cancer 2008; 15 (3): 701–20.
12. Rinke A, Muller H, Schade-Brittinger C et al. R Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol 2009; 27: 4656–63.
13. Ruszniewski P, Ish-Shalom S, Wymenga M et al. Rapid and sustained relief from the symptoms of carcinoid syndrome: results from an open 6-month study of the 28-day prolonged-release formulation of lanreotide. Neuroendocrinology 2004; 80 (4): 244–51.
14. Caplin ME, Pavel M, Ćwikła JB et al. N Lanreotide in metastatic enteropancreatic neuroendocrine tumors. CLARINET Investigators. Engl J Med 2014; 371 (3): 224–33.
15. 12th Annual Conferens for the Diagnosis and Treatment of Neuroendocrine Tumor Disease 11–13 March 2015, Barcelona, Spain, ENETS abstractbook.
2. Lahlou H, Guillermet J, Hortala M et al. Molecular signaling of somatostatin receptors. Ann N Y Acad Sci 2004; 1014: 121–31.
3. Rorstad O. Prognostic indicators for carcinoid neuroendocrine tumors of the gastrointestinal tract. J Surg Oncol 2005; 89: 151–60.
4. Bajetta E, Carnagi С, Ferrari L et al. The role of somatostatin analogues in the treatment of gastroenteropancreatic endocrine tumors. Digest 1996; 57 (Suppl. 1): 72–7.
5. Battershill PE, Clissold SP. Octreotide: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in conditions associated with excessive peptide secretion. Drugs 1989; 38: 658–702.
6. Kvols LK, Moertel CG, O'Connell MJ et al. Treatment of the malignant carcinoid syndrome. Evaluation of a long-acting somatostatin analogue. N Engl J Med 1986; 315 (11): 663–6.
7. Lightman S. Somatuline autogel: An eхtended release lanreotide formularion. Hosp 2002; 315: 246–54.
8. Oberg K, Kvols LK, Caplin M et al. Consensus report on the se of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system. Ann Oncol 2004; 15 (6): 966–73.
9. Ricci S, Antonuzzo A, Galli L et al. Long-acting depot lanreotide in the treatment of patients with advanced neuroendocrine tumors. Am J Clin Oncol 2000; 23 (4): 412–5.
10. Kaltsas GA, Stefanidou Z, Papadogias D, Grossman AB. Treatmentof advanced neuroendocrine tumors with the radiolabelled somatostatin analogue octreotide. Hormones (Athens). 2002; 1 (3): 149–56.
11. Grozinssky-Glasberg S, Shimov I, Korbonits M, Grossvan AB. Somatostatin analogues in control of the control of neuroendocrine tumors: efficacy and mechanisms. Endocr Relat Cancer 2008; 15 (3): 701–20.
12. Rinke A, Muller H, Schade-Brittinger C et al. R Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol 2009; 27: 4656–63.
13. Ruszniewski P, Ish-Shalom S, Wymenga M et al. Rapid and sustained relief from the symptoms of carcinoid syndrome: results from an open 6-month study of the 28-day prolonged-release formulation of lanreotide. Neuroendocrinology 2004; 80 (4): 244–51.
14. Caplin ME, Pavel M, Ćwikła JB et al. N Lanreotide in metastatic enteropancreatic neuroendocrine tumors. CLARINET Investigators. Engl J Med 2014; 371 (3): 224–33.
15. 12th Annual Conferens for the Diagnosis and Treatment of Neuroendocrine Tumor Disease 11–13 March 2015, Barcelona, Spain, ENETS abstractbook.
2. Lahlou H, Guillermet J, Hortala M et al. Molecular signaling of somatostatin receptors. Ann N Y Acad Sci 2004; 1014: 121–31.
3. Rorstad O. Prognostic indicators for carcinoid neuroendocrine tumors of the gastrointestinal tract. J Surg Oncol 2005; 89: 151–60.
4. Bajetta E, Carnagi С, Ferrari L et al. The role of somatostatin analogues in the treatment of gastroenteropancreatic endocrine tumors. Digest 1996; 57 (Suppl. 1): 72–7.
5. Battershill PE, Clissold SP. Octreotide: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in conditions associated with excessive peptide secretion. Drugs 1989; 38: 658–702.
6. Kvols LK, Moertel CG, O'Connell MJ et al. Treatment of the malignant carcinoid syndrome. Evaluation of a long-acting somatostatin analogue. N Engl J Med 1986; 315 (11): 663–6.
7. Lightman S. Somatuline autogel: An eхtended release lanreotide formularion. Hosp 2002; 315: 246–54.
8. Oberg K, Kvols LK, Caplin M et al. Consensus report on the se of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system. Ann Oncol 2004; 15 (6): 966–73.
9. Ricci S, Antonuzzo A, Galli L et al. Long-acting depot lanreotide in the treatment of patients with advanced neuroendocrine tumors. Am J Clin Oncol 2000; 23 (4): 412–5.
10. Kaltsas GA, Stefanidou Z, Papadogias D, Grossman AB. Treatmentof advanced neuroendocrine tumors with the radiolabelled somatostatin analogue octreotide. Hormones (Athens). 2002; 1 (3): 149–56.
11. Grozinssky-Glasberg S, Shimov I, Korbonits M, Grossvan AB. Somatostatin analogues in control of the control of neuroendocrine tumors: efficacy and mechanisms. Endocr Relat Cancer 2008; 15 (3): 701–20.
12. Rinke A, Muller H, Schade-Brittinger C et al. R Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol 2009; 27: 4656–63.
13. Ruszniewski P, Ish-Shalom S, Wymenga M et al. Rapid and sustained relief from the symptoms of carcinoid syndrome: results from an open 6-month study of the 28-day prolonged-release formulation of lanreotide. Neuroendocrinology 2004; 80 (4): 244–51.
14. Caplin ME, Pavel M, Ćwikła JB et al. N Lanreotide in metastatic enteropancreatic neuroendocrine tumors. CLARINET Investigators. Engl J Med 2014; 371 (3): 224–33.
15. 12th Annual Conferens for the Diagnosis and Treatment of Neuroendocrine Tumor Disease 11–13 March 2015, Barcelona, Spain, ENETS abstractbook.
________________________________________________
2. Lahlou H, Guillermet J, Hortala M et al. Molecular signaling of somatostatin receptors. Ann N Y Acad Sci 2004; 1014: 121–31.
3. Rorstad O. Prognostic indicators for carcinoid neuroendocrine tumors of the gastrointestinal tract. J Surg Oncol 2005; 89: 151–60.
4. Bajetta E, Carnagi С, Ferrari L et al. The role of somatostatin analogues in the treatment of gastroenteropancreatic endocrine tumors. Digest 1996; 57 (Suppl. 1): 72–7.
5. Battershill PE, Clissold SP. Octreotide: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in conditions associated with excessive peptide secretion. Drugs 1989; 38: 658–702.
6. Kvols LK, Moertel CG, O'Connell MJ et al. Treatment of the malignant carcinoid syndrome. Evaluation of a long-acting somatostatin analogue. N Engl J Med 1986; 315 (11): 663–6.
7. Lightman S. Somatuline autogel: An eхtended release lanreotide formularion. Hosp 2002; 315: 246–54.
8. Oberg K, Kvols LK, Caplin M et al. Consensus report on the se of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system. Ann Oncol 2004; 15 (6): 966–73.
9. Ricci S, Antonuzzo A, Galli L et al. Long-acting depot lanreotide in the treatment of patients with advanced neuroendocrine tumors. Am J Clin Oncol 2000; 23 (4): 412–5.
10. Kaltsas GA, Stefanidou Z, Papadogias D, Grossman AB. Treatmentof advanced neuroendocrine tumors with the radiolabelled somatostatin analogue octreotide. Hormones (Athens). 2002; 1 (3): 149–56.
11. Grozinssky-Glasberg S, Shimov I, Korbonits M, Grossvan AB. Somatostatin analogues in control of the control of neuroendocrine tumors: efficacy and mechanisms. Endocr Relat Cancer 2008; 15 (3): 701–20.
12. Rinke A, Muller H, Schade-Brittinger C et al. R Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol 2009; 27: 4656–63.
13. Ruszniewski P, Ish-Shalom S, Wymenga M et al. Rapid and sustained relief from the symptoms of carcinoid syndrome: results from an open 6-month study of the 28-day prolonged-release formulation of lanreotide. Neuroendocrinology 2004; 80 (4): 244–51.
14. Caplin ME, Pavel M, Ćwikła JB et al. N Lanreotide in metastatic enteropancreatic neuroendocrine tumors. CLARINET Investigators. Engl J Med 2014; 371 (3): 224–33.
15. 12th Annual Conferens for the Diagnosis and Treatment of Neuroendocrine Tumor Disease 11–13 March 2015, Barcelona, Spain, ENETS abstractbook.
Авторы
Г.С.Емельянова*1, А.Е.Кузьминов2, Н.Ф.Орел2,3, А.С.Одинцова2, А.А.Маркович2, А.А.Кузнецова2, В.А.Горбунова2
1 ГБОУ ВПО Московский государственный медико-стоматологический университет им. А.И.Евдокимова Минздрава России. 127473, Россия, Москва, ул. Делегатская, д. 20, стр. 1;
2 ФГБУ Российский онкологический научный центр им. Н.Н.Блохина Минздрава России. 115478, Россия, Москва, Каширское ш., д. 23;
3 ГБОУ ДПО Российская медицинская академия последипломного образования Минздрава России. 123995, Россия, Москва, ул. Баррикадная, д. 2/1
*docgalina@mail.ru
1 A.I.Evdokimov Moscow State Medical and Dental University of the Ministry of Health of the Russian Federation.127473, Russian Federation, Moscow, ul. Delegatskaia, d. 20, str. 1;
2 N.N.Blokhin Russian Cancer of the Ministry of Health of the Russian Federation. 115478, Russian Federation, Moscow, Kashirskoe sh., d. 23
3 Russian Medical Academy of Postgraduate Education of the Ministry of Health of the Russian Federation. 125993, Russian Federation, Moscow, ul. Barrikadnaia, d. 2/1
*docgalina@mail.ru
1 ГБОУ ВПО Московский государственный медико-стоматологический университет им. А.И.Евдокимова Минздрава России. 127473, Россия, Москва, ул. Делегатская, д. 20, стр. 1;
2 ФГБУ Российский онкологический научный центр им. Н.Н.Блохина Минздрава России. 115478, Россия, Москва, Каширское ш., д. 23;
3 ГБОУ ДПО Российская медицинская академия последипломного образования Минздрава России. 123995, Россия, Москва, ул. Баррикадная, д. 2/1
*docgalina@mail.ru
________________________________________________
1 A.I.Evdokimov Moscow State Medical and Dental University of the Ministry of Health of the Russian Federation.127473, Russian Federation, Moscow, ul. Delegatskaia, d. 20, str. 1;
2 N.N.Blokhin Russian Cancer of the Ministry of Health of the Russian Federation. 115478, Russian Federation, Moscow, Kashirskoe sh., d. 23
3 Russian Medical Academy of Postgraduate Education of the Ministry of Health of the Russian Federation. 125993, Russian Federation, Moscow, ul. Barrikadnaia, d. 2/1
*docgalina@mail.ru
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.